Diclofenac - Depomed

Drug Profile

Diclofenac - Depomed

Alternative Names: Lynxorb™; ProSorb-D™; XP 21L; Zipsor

Latest Information Update: 04 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AAIPharma
  • Developer Depomed
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute pain

Most Recent Events

  • 21 Jun 2012 Depomed acquires diclofenac from Xanodyne
  • 03 May 2010 Diclofenac licensed to Ferring in USA for the treatment of Acute pain (orthopaedics only)
  • 12 Nov 2009 Launched for Acute pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top